Latest Financial Results
Q1 2019
Quarter Ended Mar 31, 2019
Stock Information
Company Overview
HJLI specializes in developing and manufacturing bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two product candidates: the porcine tissue based VenoValve®, which is intended to be surgically implanted in the deep venous system of the leg to treat Chronic Venue Insufficiency and the CoreoGraft®, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery.
Investor Contact Information
Company
Hancock Jaffe Laboratories, Inc.
70 Doppler
Irvine, CA 92618
T: 949-261-2900
F: 949-261-2992
Investor Relations
MZ North America
Chris Tyson
Managing Director
T: 949-491-8235
HJLI@mzgroup.us
Transfer Agent
V Stock Transfer LLC